Drugs Five Years Later
Bromocriptine
- MARY LEE VANCE, M.D.;
- WILLIAM S. EVANS, M.D.; and
- MICHAEL O. THORNER, M.B.
Abstract
Bromocriptine, a specific dopamine receptor agonist, has been used for the treatment of various hyperprolactinemic conditions and as adjunctive therapy for acromegaly (with or without concomitant hyperprolactinemia) and Parkinson's disease. Bromocriptine is extremely effective in suppressing prolactin secretion regardless of the cause, in restoring gonadal function and fertility, and in decreasing the size of prolactin-secreting pituitary tumors. Most patients with acromegaly have clinical improvement with this drug. When bromocriptine is added to a regimen of levodopa or carbidopa, patients with Parkinson's disease frequently have additional clinical improvement and, in most patients, the levodopa or carbidopa dose can be reduced. Withdrawal of bromocriptine therapy is associated in most patients with reversal of its beneficial effects—return of hyperprolactinemia, return of excess growth hormone secretion, and exacerbation of Parkinson's disease.
Article and Author Information
-
▸From the Department of Internal Medicine, University of Virginia Medical Center; Charlottesville, Virginia.
-
Grant support: in part by General Clinical Research Grants RR 847, R01 HD13197, and CIA 1 K03-HD-00439 from the U. S. Public Health Service; and a grant from Sandoz, Inc.
-
▸Requests for reprints should be addressed to Michael O. Thorner, M.B.; Box 511, University of Virginia Hospital; Charlottesville, VA 22908.
- © 1984 American College of Physicians
RSS Feeds









